Heat Biologics Inc (NASDAQ:HTBX) CEO Jeff Wolf talks to Proactive about how the Durham, North Carolina-based biotechnology company plans to proceed with its Phase 3 registration pathways for its lead therapy HS-110 in combination with a checkpoint inhibitor. What's more, Wolf spoke about the status of the group's coronavirus vaccine, as well as the company's current financial health.
Heat Biologics updates on its achievements in 2020, and expectations for 2021
